214 related articles for article (PubMed ID: 30185432)
1. How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes.
Steensma DP
Blood; 2018 Oct; 132(16):1657-1663. PubMed ID: 30185432
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
Bejar R
Curr Hematol Malig Rep; 2015 Sep; 10(3):282-91. PubMed ID: 26126599
[TBL] [Abstract][Full Text] [Related]
3. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
5. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
6. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia.
Zheng G; Chen P; Pallavajjalla A; Haley L; Gondek L; Dezern A; Ling H; De Marchi F; Lin MT; Gocke C
Am J Hematol; 2019 Oct; 94(10):1141-1148. PubMed ID: 31350794
[TBL] [Abstract][Full Text] [Related]
8. Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
[TBL] [Abstract][Full Text] [Related]
9. [Sequential acquisition of mutations in myelodysplastic syndromes].
Makishima H
Rinsho Ketsueki; 2017; 58(10):1828-1837. PubMed ID: 28978821
[TBL] [Abstract][Full Text] [Related]
10. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
11. Mutational profiling in patients with MDS: ready for every-day use in the clinic?
Bacher U; Kohlmann A; Haferlach T
Best Pract Res Clin Haematol; 2015 Mar; 28(1):32-42. PubMed ID: 25659728
[TBL] [Abstract][Full Text] [Related]
12. Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.
Hebeda KM; Tzankov A; Boudova L; Saft L; Hasserjian RP; de Boer M; Fend F; Orazi A; Leguit R
Pathobiology; 2019; 86(1):62-75. PubMed ID: 29982244
[TBL] [Abstract][Full Text] [Related]
13. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
14. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
15. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
16. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
[TBL] [Abstract][Full Text] [Related]
17. Implications of molecular genetic diversity in myelodysplastic syndromes.
Bejar R
Curr Opin Hematol; 2017 Mar; 24(2):73-78. PubMed ID: 27875374
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics in myelodysplastic syndromes.
Haferlach T
Leuk Res; 2012 Dec; 36(12):1459-62. PubMed ID: 22986016
[TBL] [Abstract][Full Text] [Related]
19. The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes.
Steensma DP
Best Pract Res Clin Haematol; 2017 Dec; 30(4):295-300. PubMed ID: 29156198
[TBL] [Abstract][Full Text] [Related]
20. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
Kohlmann A; Bacher U; Schnittger S; Haferlach T
Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
